Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Evolving Therapies in Esophageal Carcinoma, An Issue of Thoracic Surgery Clinics -  Wayne Hofstetter

Evolving Therapies in Esophageal Carcinoma, An Issue of Thoracic Surgery Clinics (eBook)

eBook Download: EPUB
2013 | 1. Auflage
100 Seiten
Elsevier Health Sciences (Verlag)
978-0-323-24238-7 (ISBN)
Systemvoraussetzungen
65,12 inkl. MwSt
(CHF 63,60)
Der eBook-Verkauf erfolgt durch die Lehmanns Media GmbH (Berlin) zum Preis in Euro inkl. MwSt.
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
This issue of Thoracic Surgery Clinics devoted to Therapy for Esophageal Cancer will be Guest Edited by Dr. Wayne Hofstetter. Articles in this issue include: Radiographic and Endoscopic staging of esophageal cancer; Endoscopic management of HGD/Early stage esophageal cancer; Induction chemotherapy for esophageal cancer; Personalizing therapy for esophageal cancer patients; Surgery for esophageal cancer: Goals of resection and optimizing outcomes (Lymph node dissection in esophageal cancer/R0 Resection); Standardizing Esophagectomy Complications; Adjuvant therapy (post-op) for esophageal cancer; Definitive CXRT for esophageal cancer; Salvage Esophagectomy in the management of recurrent or persistent esophageal cancer; and Quality of life after curative resection for esophageal cancer.
This issue of Thoracic Surgery Clinics devoted to Therapy for Esophageal Cancer will be Guest Edited by Dr. Wayne Hofstetter. Articles in this issue include: Radiographic and Endoscopic staging of esophageal cancer; Endoscopic management of HGD/Early stage esophageal cancer; Induction chemotherapy for esophageal cancer; Personalizing therapy for esophageal cancer patients; Surgery for esophageal cancer: Goals of resection and optimizing outcomes (Lymph node dissection in esophageal cancer/R0 Resection); Standardizing Esophagectomy Complications; Adjuvant therapy (post-op) for esophageal cancer; Definitive CXRT for esophageal cancer; Salvage Esophagectomy in the management of recurrent or persistent esophageal cancer; and Quality of life after curative resection for esophageal cancer.

Radiographic and Endosonographic Staging in Esophageal Cancer


Mark J. Krasna, MDabMKrasna@meridianhealth.com,     aMeridian Cancer Care, 1945 Route 33-Ackerman South, Room 553, Neptune, NJ 07753, USA; bRutgers-Robert Wood Johnson Medical School, 125 Paterson Street, New Brunswick, NJ 08903, USA

∗Meridian Cancer Care, 1945 Route 33-Ackerman South, Room 553, Neptune, NJ 07753, USA.

Radiographic imaging using computed tomographic (CT) scan and positron emission tomography/CT are primarily helpful in identifying distant metastases. In general, if patients have evidence of lymph node involvement that is proved pathologically by endoscopic ultrasound/fine needle aspiration, this information is considered definitive, and the patient can be referred for the appropriate stage-specific therapy. Laparoscopy combined with laparoscopic ultrasound and peritoneal lavage has been shown to have sensitivity of 67% and specificity of 92% for lymph node disease. Thoracoscopy may help identify involved lymph node in the mediastinum before resection and help determine the field of radiation.

Keywords

Esophageal cancer • Staging • Imaging • Radiographic staging • Esophageal ultrasound

Key points


• Staging is crucial to appropriate therapy of esophageal cancer.

• Radiographic imaging is primarily helpful in identifying distant metastases.

• Endoscopic ultrasound (EUS) and EUS/fine-needle aspiration are crucial to determining respectability and extent of locoregional disease.

• Modern staging using computed tomography and positron emission tomography can identify metastatic disease as well as predict response to therapy.

Introduction


Staging of esophageal cancer is critical to determining optimal therapy in all patients with this disease. Current use of multimodality therapy in these patients requires a clear understanding of the stage at the time of presentation. This understanding allows us to avoid unnecessary treatment in patients with limited, local disease as well as allows those patients with metastatic disease to receive appropriate treatment and palliation as soon as possible.

Role of staging


Current staging systems depend primarily on the depth of invasion in the wall, the presence of lymph nodes involved with tumor, and the identification of distant metastatic disease.1 The allocation of tumor-node-metastasis (TNM) stage-to-stage groupings is determined by survival; this has been confirmed by the report from the World Esophageal Cancer Consortium, which documented the relationship between staging and survival.2 The order of testing should allow the treating physicians to arrive at the decision regarding whether definitive treatment is feasible as quickly as possible (Box 1).1,3

Box 1   TNM classifications

Grade

GX: Grade cannot be assessed

G1: Well differentiated

G2: Moderately differentiated

G3: Poorly differentiated

G4: Undifferentiated

Primary Tumor (T)

TX: Primary tumor cannot be assessed

T0: No evidence of primary tumor

Tis: High-grade dysplasia

T1a: Tumor invading lamina propria or muscularis mucosae

T1b: Tumor invading submucosa

T2: Tumor invading muscularis propria

T3: Tumor invading adventitia

T4a: Tumor invading pleura, pericardium, or diaphragm

T4b: Tumor invading other adjacent structures

Regional Lymph Nodes (N)

NX: Regional lymph nodes cannot be assessed

N0: No regional lymph node metastasis

N1: Regional lymph node metastasis involving 1–2 nodesa

N2: Regional lymph node metastasis involving 3–6 nodesa

N3: Regional lymph node metastasis involving 7 or more nodesa

a Regional lymph nodes extend from periesophageal cervical to celiac nodes.

Distant Metastasis (M)

MX: Distant metastasis cannot be assessed

M0: No distant metastasis

M1: Nonregional lymph node metastasis or distant metastasis

Stage

Stage 0: T0 N0 M0, any grade; Tis N0 M0, any grade

Stage IA: T1 N0 M0, grade 1–2

Stage IB: T1 N0 M0, grade 3; T1 N0 M0, grade 4; T2 N0 M0, grade 1–2

Stage IIA: T2 N0 M0, grade 3–4

Stage IIB: T3 N0 M0; T0 N1 M0, any grade; T1–2 N1 M0, any grade

Stage IIIA: T0–2 N2 M0, any grade; T3 N1 M0, any grade; T4a N0 M0, any grade

Stage IIIB: T3 N2 M0, any grade

Stage IIIC: T4a N1–2 M0, any grade; T4b any N M0, any grade; any T N3 M0, any grade

Stage IV: any T, any N, M1, any grade

The most common presenting signs of squamous cell carcinoma or locally advanced adenocarcinoma are dysphagia and odynophagia. For patients with Barrett esophagus and early-stage adenocarcinoma, reflux is the most common presenting sign. Severe weight loss usually occurs after swallowing difficulties begin. Upper esophageal tumors can involve the recurrent laryngeal nerve, causing the patient to have a hoarse voice. Phrenic nerve involvement can trigger hiccups. A postprandial or paroxysmal cough may indicate the presence of an esophagotracheal or esophagobronchial fistula resulting from local invasion by a tumor.4,5

Radiography and upper endoscopy are the most important investigations for evaluating the presence of and extent of esophageal cancer. If esophageal cancer is suspected, the first investigation is usually an upper gastrointestinal endoscopy (esophagogastroduodenoscopy). This endoscopy allows assessment of any obstruction and biopsy to confirm the histology of mucosal lesions.6 Confocal laser endoscopy with targeted biopsy can improve the diagnostic yield for neoplasia and decrease the number of mucosal biopsies in patients in the surveillance group. Endoscopy can identify benign causes of obstructive symptoms as well as allow an opportunity for dilatation and immediate palliation.7

Radiographic diagnosis and staging


A barium swallow is sometimes done before endoscopy to confirm an obstruction, but this is not routinely required. Barium swallow was used in the past as a tool to identify esophageal cancer before endoscopy. Although it can provide information on tumor length, features such as location and size of the tumor are more accurately assessed by endoscopy. Barium studies cannot accurately rule out benign disease or rule in malignancy without a biopsy and are therefore of little value as an initial diagnostic test, unless one is suspicious of a tracheoesophageal fistula. They may provide supportive data in the differentiation of gastroesophageal junction tumors from gastric tumors where large tumors are seen on retroflexion.8

Computed tomography (CT) is still the gold standard for staging patients identified with esophageal cancer. This primarily allows the identification of distant metastatic disease in the lungs, abdominal viscera, and bones. In the absence of metastatic disease, CT can provide some idea of local invasiveness as a guide to determining local resectability. In specific, CT can detect contact with the airway or major blood vessels, which might be an indication of unresectability.9

CT scan of the chest and abdomen is performed if the suspicion of esophageal cancer is high or biopsy confirms the diagnosis. The CT scan assesses tumor bulk and can monitor tumor response to therapy. The CT can define whether the tumor has spread from the esophagus to regional lymph nodes and/or contiguous structures. Oral and intravenous contrast material should be used to ensure optimal pacification of the lumen and visualization of the heart, mediastinal vessels, and liver. An esophageal wall thickness greater than 5 mm is abnormal suggesting a T2 or higher lesion. T1 and T2 lesions generally show an esophageal mass thickness between 5 mm and 15 mm; T3 lesions show a thickness greater than 15 mm. T4 lesions show invasion of contiguous structures on CT and may be suspected by the presence of “contact” between the esophagus and surrounding structures, such as the airway or great vessels. In general, contact with the aorta of more than 90° circumference is considered suspicious for T4 disease.10 In addition, diaphragmatic invasion is suggested by loss of the retrocrural fat planes. Tracheal invasion may be suspected where a midesophageal tumor bulges into the posterior membranous portion of the airway. Suspicious...

Erscheint lt. Verlag 1.1.2014
Sprache englisch
Themenwelt Medizinische Fachgebiete Chirurgie Herz- / Thorax- / Gefäßchirurgie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
ISBN-10 0-323-24238-3 / 0323242383
ISBN-13 978-0-323-24238-7 / 9780323242387
Haben Sie eine Frage zum Produkt?
EPUBEPUB (Adobe DRM)

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich
Leitlinien und Studienlage

von E. Sebastian Debus; Reinhart T. Grundmann

eBook Download (2023)
Springer Berlin Heidelberg (Verlag)
CHF 48,80

von Jürgen Ennker; Volkmar Falk; Joachim Photiadis …

eBook Download (2022)
Georg Thieme Verlag KG
CHF 289,95